A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov) - Sep 15, 2026 - P1 | N=100 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2028 ➔ Oct 2028 | Trial primary completion date: Apr 2027 ➔ Nov 2027
Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
|